Annual report pursuant to Section 13 and 15(d)

Discontinued Operations (Details Narrative)

v3.19.3
Discontinued Operations (Details Narrative) - USD ($)
1 Months Ended 3 Months Ended 12 Months Ended
Sep. 27, 2017
Dec. 31, 2017
Dec. 31, 2016
Dec. 31, 2018
Dec. 31, 2017
Sep. 18, 2018
Sep. 29, 2016
Jul. 19, 2016
Preferred stock shares designated       5,000,000   5,000,000    
Number of common stock issued on conversion       $ 8,128,044 $ 7,306,314      
Series F Preferred Stock [Member]                
Preferred stock shares designated   1,750,000   1,750,000 1,750,000      
Preferred stock stated value $ 1,750,000 $ 17,500   $ 17,500 $ 17,500      
Convertible terms of conversion feature The Series F Preferred Stock issued effective September 27, 2017 has an aggregate stated value of $1,750,000, and is convertible into shares of the Company's common stock at any time after the one-year anniversary of the closing date at a conversion price per common share equal to the greater of $14,625 or the average closing sales price of the Company's common stock for the 10 trading days immediately preceding the conversion.              
Shares converted into debt            
Number of common stock issued on conversion            
Series F Preferred Stock [Member] | Minimum [Member]                
Conversion price per share $ 14,625              
Series F Preferred Stock [Member] | Maximum [Member]                
Shares converted into debt 120              
Number of common stock issued on conversion $ 174,097              
Genomas, Inc. [Member]                
Due to related party     $ 400,000          
Goodwill impairment charge   $ 1,000,000            
Genomas, Inc. [Member] | Hartford Healthcare Corporation [Member]                
Equity ownership percentage               15.00%
Notes payable               $ 1,500,000
Cash               $ 250,000
Genomas Acquisition [Member] | Advanced Molecular Services Group [Member]                
Goodwill impairment charge         $ 914,972      
Stock Purchase Agreement [Member] | Genomas, Inc. [Member]                
Equity ownership percentage             85.00%  
Previously paid amount expensed     $ 1,000,000          
Stock Purchase Agreement [Member] | Genomas, Inc. [Member] | Series F Preferred Stock [Member]                
Preferred stock shares designated             1,750,000